Rehovot, Israel – April 30, 2020 – Evogene Ltd. (NASDAQ, TASE: EVGN), leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission (the “SEC”).
The annual report, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov/ as well as via the Company’s website at http://www.evogene.com/investor-relations. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to the Company Media Contact: firstname.lastname@example.org.
About Evogene Ltd.:
Evogene (NASDAQ:EVGN, TASE: EVGN.TA) is a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, including human health, agriculture, and industrial applications, by utilizing cutting edge computational biology technologies. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. For more information, please visit www.evogene.com
Forward Looking Statements
This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its